文献速递神经肿瘤

靶向基因表达生物标志物预测临床低风险脑膜瘤复发

A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence.
PubMed 文献 · Neuro Oncol · 2025-01-01

这项多中心回顾性队列研究纳入723例脑膜瘤患者,评估34基因表达生物标志物及风险评分。结果显示该生物标志物可将51.3%的临床低风险脑膜瘤归为分子中风险、9.5%归为分子高风险,结合切除程度可识别19.8%局部无复发生存和总生存不佳的临床低风险脑膜瘤。风险评分对所有WHO级别、切除程度及新发或复发患者的局部无复发生存具有预后价值(风险评分每增加0.1,HR 1.89,95%CI 1.58-2.25)。

要点

  • 靶向基因表达谱可将51.3%临床低风险脑膜瘤归为分子中风险、9.5%归为分子高风险。
  • 结合基因表达生物标志物与切除程度,19.8%临床低风险脑膜瘤局部无复发生存和总生存不佳。
  • 风险评分每增加0.1,局部无复发生存HR 1.89(95%CI 1.58-2.25)。

核心结论

  • 靶向基因表达谱可识别可能术后复发的临床低风险脑膜瘤。

研究设计与样本

  • 多中心回顾性队列研究,纳入4家机构1992年至2023年治疗的723例脑膜瘤患者,所有样本均未用于生物标志物的发现或训练,其中265例既往未报道。

主要发现

  • 共626例WHO 1级脑膜瘤(490例全切除,126例次全切除)和97例WHO 2级全切除脑膜瘤。
  • 靶向基因表达谱将51.3%的临床低风险脑膜瘤归为分子中风险,9.5%归为分子高风险。
  • 结合基因表达生物标志物与切除程度,19.8%的临床低风险脑膜瘤局部无复发生存和总生存不佳,包括7.1%的新诊断WHO 1级全切除脑膜瘤。
  • 风险评分对所有WHO级别、切除程度及新发或复发患者的局部无复发生存具有预后价值(风险评分每增加0.1,HR 1.89,95%CI 1.58-2.25)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite reassuring clinical and histological features, low-grade meningiomas can recur after surgery. Targeted gene expression profiling improves risk stratification of meningiomas, but the utility of this approach for clinical low-risk meningiomas is incompletely understood. METHODS: This was a multicenter retrospective cohort study of meningiomas from patients who were treated at 4 institutions from 1992 to 2023. Adult patients with newly diagnosed or recurrent World Health Organization (WHO) grade 1 meningiomas that were treated with gross total resection (GTR) or subtotal resection (STR), or newly diagnosed WHO grade 2 meningiomas that were treated with GTR, were included. A 34-gene expression biomarker and gene expression risk score (continuous from 0 to 1) was evaluated in all samples. RESULTS: The study cohort was comprised of 723 patients, none of which were used for discovery or training of the gene expression biomarker and 265 of which were previously unreported. There were 626 WHO grade 1 meningiomas, 490 with GTR and 126 with STR, and 97 WHO grade 2 meningiomas with GTR. Targeted gene expression profiling classified 51.3% of clinical low-risk meningiomas as molecular intermediate-risk and 9.5% as molecular high-risk. Combining the gene expression biomarker with the extent of resection revealed that 19.8% of clinical low-risk meningiomas had unfavorable local freedom from recurrence (LFFR) and overall survival (OS), including 7.1% of newly diagnosed WHO grade 1 meningiomas with GTR. The risk score was prognostic for LFFR (HR per 0.1 increase in risk score 1.89, 95% CI: 1.58-2.25) across all WHO grades, extents of resection, and newly diagnosed or recurrent presentations. CONCLUSIONS: Targeted gene expression profiling can identify clinical low-risk meningiomas that are likely to recur after surgery.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Nguyen MP, Morshed RA, Youngblood MW, et al. A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence. Neuro Oncol. 2025. PMID: 39340366. doi:10.1093/neuonc/noae198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。